Corpus Intelligence IC Memo — SAGE REHAB HOSPITAL 2026-04-26 17:22 UTC
IC Memo — SAGE REHAB HOSPITAL
Investment Committee Memorandum | LA | 20 beds | Grade C | EBITDA uplift $987K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SAGE REHAB HOSPITAL

CCN 193078 | E. BATON ROUGE PARISH, LA | 20 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SAGE REHAB HOSPITAL is a 20-bed suburban community hospital in E. BATON ROUGE PARISH, LA with $13.4M in net patient revenue and a 2.4% operating margin. The hospital serves a payer mix of 39.6% Medicare, 2.9% Medicaid, and 57.5% commercial.

Thesis: Turnaround. Our ML models identify $987K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.4% to 9.8% (+738bps).

Net Revenue HCRIS$13.4M
Current EBITDA COMPUTED$322K
Operating Margin COMPUTED2.4%
Occupancy HCRIS72.3%
Revenue / Bed COMPUTED$669K
Net-to-Gross HCRIS99.2%
Distress Probability ML51.4%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
126
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 2.4% places it above the state median. Among 126 size-comparable peers (10-40 beds), the median margin is -2.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-40), prioritizing same-state peers. 126 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SAGE REHAB HOSPITAL (Target)LA20$13.4M2.4%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%
BYRD REGIONAL HOSPITALLA39$61.1M2.5%
THE SPINE HOSPITAL OF LOUISIANLA23$57.4M35.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $987K (738bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$281K+210bp18mo
Cost to Collect4.5%2.5%$268K+200bp12mo
Denial Rate Reduction12.0%6.5%$266K+199bp12mo
A/R Days Reduction5200.0%3800.0%$163K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+7bp6mo

5. EBITDA Bridge

Net Collection Rate
$281K
Cost to Collect
$268K
Denial Rate Reduction
$266K
A/R Days Reduction
$163K
Clean Claim Rate
$10K
Total EBITDA Uplift$987K
Current EBITDA$322K
+ RCM Uplift+$987K
Pro Forma EBITDA$1.3M
Current Margin2.4%
Pro Forma Margin9.8%
WC Released (1x)$513K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$496K$12.0M24.19x89.1%
Base (11x exit)10.0x11.0x$496K$13.4M26.94x93.2%
Bull Case9.0x11.0x$446K$16.8M37.59x106.5%
Bull (12x exit)9.0x12.0x$446K$18.4M41.30x110.5%
Bear Case11.0x10.0x$545K$6.9M12.65x66.1%
Bear (11x exit)11.0x11.0x$545K$7.8M14.24x70.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighElevated distress probabilityModel estimates 51.4% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 126 hospitals with 10-40 beds
  • Same-state prioritization (n=127)
  • Comp margins: P25=-15.8% / P50=-2.9% / P75=7.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.